Abstract
Participant enrollment in clinical trials is challenged by a multitude of structural-, clinical-, physician-, and individual-level barriers to participation.1 In addition to slow clinical trial accrual, there is often under-representation of racial/ethnic minorities who encounter even greater barriers to participation.2,3 The coronavirus disease 2019 (COVID-19) pandemic has further challenged participant enrollment.4 Nationally representative data on attitudes toward clinical trials are limited.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
